{"title":"[Urethral prolapse: an unknown diagnosis in pediatrics].","authors":"Sybille Gobert, Aurélien Partoune, Arnaud Taxhet, Anne-Simone Parent","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Urethral prolapse is defined as the protrusion of the distal urethral mucosa in a circular shape through the external meatus. It is a rare condition with an estimated incidence of 1 in 3,000 cases. It primarily affects prepubescent girls of African origin and postmenopausal women of Caucasian origin. While generally asymptomatic, this condition can also cause vaginal bleeding, dysuria, hematuria, urinary urgency, urinary retention and dyspareunia. The pathophysiology of this condition is debated. Increases in intra-abdominal pressure (e.g. coughing, constipation or trauma) and a hypo-estrogenic environment are the most common risk factors. In most cases, the diagnosis is clinical. It is important to consider the differential diagnosis, as this condition can include malignant pathologies (such as botryoid sarcoma and rhabdomyosarcoma), as well as sexual violence. Treatment is generally conservative for asymptomatic or paucisymptomatic cases, while more symptomatic or recurrent cases may benefit from surgery. This article presents the case of a three-year-old girl of African origin who was referred to the local Sexual Assault Center (SAC) for suspected sexual abuse, after vaginal bleeding of unknown origin was discovered upon her return from school.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 3","pages":"133-137"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Celena Azouaoui, Vincent Heinen, Olivier Bonhomme, Renaud Louis
{"title":"[How I explore … diaphragmatic dysfunction].","authors":"Celena Azouaoui, Vincent Heinen, Olivier Bonhomme, Renaud Louis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diaphragmatic dysfunction, whether unilateral or bilateral, partial or complete, is often an overlooked cause of dyspnea, sleep disturbances, and, in more advanced stages, chronic alveolar hypoventilation. It may result from injury to the phrenic nerve, the diaphragm muscle itself, or central nervous system pathways. The diagnosis is frequently suspected when an elevated hemidiaphragm is incidentally observed on chest imaging. A comprehensive assessment combining clinical examination, pulmonary function tests, arterial blood gas analysis, and targeted imaging is essential to confirm the dysfunction, identify its underlying cause, evaluate its severity, and guide management. In its advanced form, chronic hypercapnic respiratory failure may occur, often requiring non-invasive ventilation in addition to treatment of the underlying cause. This review outlines a structured and practical approach to the evaluation of diaphragmatic dysfunction, incorporating recent advances and key clinical considerations.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 3","pages":"162-170"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Understand, integrate, decide].","authors":"Patrizio Lancellotti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This issue highlights the growing complexity of modern medicine through diverse clinical situations, ranging from rare diseases to everyday practice challenges. It emphasizes the central role of clinical reasoning in data integration and medical decision-making.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 3","pages":"127-128"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Bettonville, Claire Maquet, Pierre Peters, Jo Caers
{"title":"[Acquired hemophilia A secondary to marginal zone lymphoma].","authors":"Laura Bettonville, Claire Maquet, Pierre Peters, Jo Caers","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acquired hemophilia A (AHA) is a rare but potentially life-threatening disorder characterized by the development of inhibitors against factor VIII. In 30-50 % of cases, AHA is associated with an underlying condition. We present a case of acquired hemophilia A secondary to marginal zone lymphoma. The diagnosis of AHA should raise suspicion for an underlying neoplastic process, prompting a thorough diagnostic workup. Although etiology remains unidentified in approximately half of AHA cases, it is crucial to maintain a high index of suspicion for malignancy, as neoplastic diseases may emerge even after treatment of AHA. The management of acquired hemophilia A consists of three main objectives : control of active bleeding, eradication of the inhibitor, and treatment of the underlying disease.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 3","pages":"129-132"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benoît Lahaye-Goffart, Nathalie Layios, Vincent Bonhomme, Marc Senard
{"title":"[Direct oral anticoagulant management for elective surgery : key points in the context of city medical practice].","authors":"Benoît Lahaye-Goffart, Nathalie Layios, Vincent Bonhomme, Marc Senard","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Practices regarding the interruption, substitution, and restart of direct oral anticoagulants (DOACs) during the perioperative period have constantly evolved since the commercialization of those medications. This may lead to uncertainties regarding their adequate management among practitioners, particularly outside the hospital. We propose a review of recent reference publications and guidelines defining DOAC management during the pre- and postoperative period for elective surgery, with the goal of providing a pratical guide for practitioners outside the hospital, including general practitioners and pharmacists. After classifying the bleeding risk of surgery or interventional procedure, we indicate how to proceed. When the bleeding risk is minimal, DOACs should be stopped 24 hours before the procedure (i.e. no intake on the day of the procedure). When the risk is moderate or high, the last intake should occur 60 to 72 hours before the procedure (4 days for dabigatran), without any bridging with low molecular weight heparins. In patients with renal insufficiency, these delays should be extended, specifically for dabigatran.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 3","pages":"150-155"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].","authors":"André Scheen, Patrizio Lancellotti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their ability to reduce major adverse cardiovascular events (MACEs) among at-risk patients living with type 2 diabetes (T2D). Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated a better control of hyperglycaemia, body weight and several cardiovascular risk factors than pure GLP-1RAs (including semaglutide) in dedicated studies of the SURPASS programme. SURPASS CVOT has the primary objective to demonstrate, in a population with T2D and atheromatous cardiovascular disease, the non-inferiority of tirzepatide regarding both efficacy and safety compared with dulaglutide, a selective GLP-RA that has already proven a significant reduction in MACEs versus placebo in the REWIND trial. Non-inferiority was met in SURPASS CVOT (p = 0.003), but not superiority of tirzepatide compared to dulaglutide (hazard ratio [HR] 0.92; 95 % confidence interval [IC] 0.83 to 1.01; P = 0.09) regarding the primary end point (reduction in MACEs). Several secondary end points tended to favour tirzepatide versus dulaglutide, among which a reduction in the incidence of all-cause deaths after four years of median follow-up (HR 0.84 ; 95 % CI 0.75 to 0.94; exploratory analysis). SURPASS CVOT, the first and unique study that used an active comparator rather than a placebo, confirms the efficacy and safety of the dual agonist tirzepatide in patients with T2D and atheromatous cardiovascular disease.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 3","pages":"187-193"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[How do I explore… a dystonia in 2026].","authors":"David Aktan, Romain Mievis, Frédérique Depierreux","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The term «dystonia» is often used imprecisely to describe a variety of conditions involving hypertonia or other alterations in muscle tone. In fact, dystonia is a hyperkinetic movement disorder, typically resulting from dysfunction of the basal ganglia, and has its own specific definition. It is characterised by repetitive muscle contractions, leading to abnormal involuntary postures or movements. Various presentations are observed depending on the topography and aetiology of the disease. In addition to a careful phenomenological analysis, diagnosis often requires genetic testing, which can sometimes lead to specific therapeutic options and genetic counselling. Treatments include botulinum toxin injections and deep brain stimulation, while the effectiveness of oral medications remains limited. This article provides an overview of the recommended investigations for dystonia, considering current reimbursement policies and the availability of equipment in Belgium.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 2","pages":"110-118"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marine Stoffels, Alexandre Jadoul, Céline Derwael, Fanny Gester, Antoine Bouquegneau, Pierre Lovinfosse
{"title":"[When inflammation gets sneaky : unmasking granulomatosis with polyangiitis with [18F]FDG PET/CT].","authors":"Marine Stoffels, Alexandre Jadoul, Céline Derwael, Fanny Gester, Antoine Bouquegneau, Pierre Lovinfosse","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Granulomatosis with polyangiitis is a rare disease that can lead to potentially fatal multisystem involvement if not properly or promptly managed. Early diagnosis is therefore crucial but may be challenging, especially because this condition often presents with nonspecific general symptoms. Sensitive imaging techniques, such as [18F]FDG PET/CT, can be useful for diagnosis, initial assessment of disease extent, and treatment response, potentially surpassing the conventional imaging methods typically used.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 2","pages":"65-69"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ines Rebia, Frédéric Piérart, Laura Allaer, Anne François, Sophie Smeets, Pierre Maton, Matthieu Thimmesch
{"title":"[Cross-sectional study of respiratory function at adolescence in children born prematurely].","authors":"Ines Rebia, Frédéric Piérart, Laura Allaer, Anne François, Sophie Smeets, Pierre Maton, Matthieu Thimmesch","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Preterm-born children, especially those born before 32 weeks of gestational age, are at increased risk for persistent respiratory complications at adolescence. This retrospective single-center study aimed to assess long-term pulmonary function in children born at < 33 weeks gestational age (GA) between 2011 and 2014 at CHC Saint-Vincent (Liège, Belgium). Evaluations, conducted between January and May 2025, included a detailed medical history, clinical examination, pulmonary function tests (PFTs), fractional exhaled nitric oxide (FeNO) measurement, and skin prick testing when indicated. Forty children aged 11 to 14 years were included. The mean age at birth was 28.7 ± 2.6 weeks GA. At adolescence, 55 % of the children reported exertional respiratory symptoms and 22.5 % had recurrent bronchitis. Mean Forced Expiratory Volume in one second (FEV1) in z-score was -0.77 ± 0.99, with no significant difference between those born before or after 28 weeks. Bronchodilator response (FEV1 in z-score) improved to -0.14 ± 0.96, which suggested a reversible obstructive component consistent with asthma. Only 10 % were receiving specialized respiratory follow-up before the study, while 37.5% required initiation or reintroduction of treatment after assessment. These findings highlight the high prevalence of undiagnosed respiratory symptoms in adolescents born preterm and underline the need for systematic screening and structured pulmonary follow-up to prevent long-term complications and improve quality of life.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 2","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tatiana Ballez, Mihaela Malanca Onica, Michel Ponchon, Philippe Purnode, Céline Goffinet
{"title":"[Amiodarone-induced hyperthyroidism : complex diagnosis and treatment].","authors":"Tatiana Ballez, Mihaela Malanca Onica, Michel Ponchon, Philippe Purnode, Céline Goffinet","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Amiodarone is among the most effective antiarrhythmic drugs and it is frequently used in the management of both supraventricular and ventricular arrhythmias, particularly in patients with impaired cardiac function. Due to its high iodine content, amiodarone therapy is associated with multiple adverse effects, most notably on thyroid function. One of the most significant endocrine complications is amiodarone-induced thyrotoxicosis. Two main subtypes have been identified - Type 1 and Type 2 - along with mixed forms, whose diagnosis may be challenging but remains essential, as therapeutic strategies vary significantly according to the underlying pathophysiology. Through the presentation of a clinical case, this article examines the different forms of amiodarone-induced thyrotoxicosis, their clinical manifestations, the diagnostic workup required to distinguish them, and the appropriate management strategies.</p>","PeriodicalId":94201,"journal":{"name":"Revue medicale de Liege","volume":"81 2","pages":"75-83"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}